Novavax , Inc. (NASDAQ:NVAX), a biotechnology company specializing in the development of vaccines with a market capitalization of $1.32 billion, has had a key contract with the Canadian government ...

Market forces rained on the parade of Novavax, Inc. (NASDAQ:NVAX) shareholders today, when the analysts downgraded their forecasts for this year. Both revenue and earnings per share (EPS) forecasts ...

A clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, only slightly lower than the 96% efficacy seen with the original strain of the ...

Novavax has begun a late-stage trial of its experimental COVID-19 vaccine in the UK, which could support filings for a licence in the UK, EU and other countries.

Breakthrough Adjuvant AB-801 Secures “Bioprocessing Excellence in Taiwan” HonorTAIPEI, Taiwan, March 13, 2025 (GLOBE NEWSWIRE ...

Healthcare & Pharmaceuticalscategory· February 28, 2025 UK health regulator approves ... on the drugmaker's manufacturing plant in India. Novavax sees royalties, reduced expenses on COVID ...

As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

Novavax , Inc. (NASDAQ:NVAX), a biotechnology company specializing in the development of vaccines with a market capitalization of $1.32 billion, has had a key contract with the Canadian government ...

GAITHERSBURG, Md. - Novavax, Inc. (NASDAQ:NVAX), a biotechnology company focusing on vaccine development with a market capitalization of $1.3 billion, has announced significant changes to its ...

Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his successor. The Company also appointed ...

Novavax (NasdaqGS:NVAX) recently announced its earnings for Q4 2024, showing a significant improvement in net loss and loss per share, which may have positively influenced its stock price movement ...